Product Image

Contributor Information

  • Name Anne-Marie Mes-Masson and Diane Provencher
  • Institute Centre Hospitalier de L’université de Montréal
  • Primary citation Sauriol A et al. 2020. Cancers. 12(8):2222. PMID: 32784519

Tool Details

  • Tool name: TOV-3392D cell line
  • Alternate names: TOV-3392D
  • Tool type: Cell Lines
  • Organism: Human
  • Donor: Grade 3 – Stage IIIC; Mutations: K-RAS2; Pre-treatment for ovarian cancer/post-treatment for breast cancer 3 years before
  • Tissue: Derived from solid tumor of patient diagnosed with epithelial ovarian cancer with a clear cell carcinoma subtype
  • Gender: Female
  • Cancer type: Gynaecologic cancer
  • Morphology: Characteristic flat epithelial morphology, grew in dense clusters, and gained little confluence
  • Growth properties: Adherent
  • CRISPR: No
  • Receptors of note: No
  • Description: Epithelial ovarian cancer cell lines spontaneously derived from solid tumors of patient diagnosed with clear-cell carcinoma suubtype. Sample was taken from the right ovary. Cell line produces tumors in mice upon SC injection
  • Research area: Cancer
  • Production details: Established using the Scrape method where tumor tissue was scraped into a 100mm plate with complete OSE medium and maintained for 40 days with medium replaced weekly.
  • Additional notes: Patient 3392 had previous personal history of breast cancer and was naive to ovarian cancer treatment but received prior chemotherapy for breast cancer. Patient was age 42 at diagnosis and har prior history of breast cancer. Treatment included 5-fluorouracil, epirubicin, cyclo-phosphamide, radiotherapy, and trastuzumab. Sampling was done during 2007.

  • For Research Use Only

Target Details

Application Details


  • Growth medium: OSE medium contains 10% FBS, 0.5ug/mL amphotericin B and 50 ug/mL gentamicin
  • Temperature: 37C
  • Atmosphere: Low oxygen conditions of 7% O2 and 5% CO2
  • Cultured in antibiotics?: Amphotericin B and Gentamicin



  •   Gaia-Oltean et al. 2021. Exp Ther Med. 21(3):243. PMID: 33603851 Canals Hernaez et al. 2020. J Immunother Cancer. 8(2):e001128. PMID: 33243933 Borzdzi?owska et al. 2022. Biomedicines. 11
  •   10(5):1116. PMID: 35625852 Meng et al. 2023. J Anim Sci. 3
  •   101:skad215. PMID: 37351870 Koni et al. 2020. Int J Mol Sci. 18
  •   21(20):7697. PMID: 33080952